The biotech reckoning is here
Price controls do not eliminate costs. They change incentives, reducing the expected return from developing medicines.
This item is an automated import from an external feed and has not yet been rewritten into a neutral C-IT-ALL summary. Read the full story at the original source below.
Read the full story at Commonwealth Beacon
Related Coverage